TheStreet reaffirmed their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Tuesday, AnalystRatingsNetwork reports.
“Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.,” TheStreet’s analyst wrote.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 268.21 on Tuesday. Regeneron Pharmaceuticals has a one year low of $136.13 and a one year high of $283.99. The stock has a 50-day moving average of $254.6 and a 200-day moving average of $226.3. The company has a market cap of $26.204 billion and a P/E ratio of 35.46.
Other equities research analysts have also recently issued reports about the stock. Analysts at BMO Capital Markets reiterated an outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note to investors on Tuesday, August 27th. Separately, analysts at Oppenheimer initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note to investors on Wednesday, August 21st. They set an outperform rating and a $300.00 price target on the stock. Finally, analysts at Zacks reiterated a neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note to investors on Tuesday, August 13th. They now have a $258.00 price target on the stock.
One investment analyst has rated the stock with a sell rating, one has given a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $257.94.
In other Regeneron Pharmaceuticals news, Director Joseph Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock on the open market in a transaction dated Friday, August 23rd. The stock was sold at an average price of $238.29, for a total transaction of $238,290.00. Following the transaction, the director now directly owns 4,000 shares in the company. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.